Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT05517811
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Liver Cancer
- Esophageal Cancer
- Colorectal Cancer
- Lung Adenocarcinoma
- Control
- Pancreas Cancer
- Biliary Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 2
- University of Colorado Denver · Aurora, CO
- UCHealth Highlands Ranch Hospital · Highlands Ranch, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.